Clinical Effect of Valsartan in Chronic Allograft Nephropathy

FENG Yuan,LIU Min,ZHANG Miao

DOI: https://doi.org/10.3969/j.issn.1671-6264.2005.03.013

2005-01-01

Abstract:Objective To evaluate the safety and efficacy of the valsartan on renal function and proteinuira in patients with chronic allograft nephropathy (CAN). Methods Seventy-two patients with biopsyproven CAN were retrospectively analyzed who had more than 6 months followup in our center. Forty-one patients received valsartan therapy (therapy group) with a average therapy time of (36.0±7.2) months compared 31 patients without these agents (control group). The clinical data such as blood pressure, serum creatinine (SCr), hemoglobin level, quantification of proteinuria, etc were dynamically observed. The primary endpoint was a ≥50% sustained increase in SCr from baseline. Secondary endpoints included allograft failure (as defined by a return to dialysis) and the combined endpoint of death and dialysis.Results There were no significant different baseline of clinical characteristics between therapy group and control group at time of biopsy. With a mean followup time of 36, 34 months, 7 of 41 (17.1%) in therapy group vs 11 of 31 (35.5%) in control group reached the primary endpoint of 50% increase in SCr (P=0.10) respectively.Fewer patients in therapy group reached the combined secondary endpoint of allograft failure or death (9.8% vs 38.7%, P0.01) with a significance; in addition, therapy group postponed the average time to the combined endpoint (53.9 vs 41.5 months,P=0.02). Noteworthily,the daily urine protein excreation fell from (2.14±2.60)g to (1.14±0.11)g (P=0.013). The common side effects in therapy group were transient hyperkalemia and anemia. Conclusion Valsartan therapy showes fairly satisfactory efficacy in slowing renal insufficiency as well as achieving significant survival benefit in the combined endpoint of allograft failure or death.